Progress, Potential, and Possibilities Podcast / Show

Send us a textDr. Vanúsia Nogueira, Ph.D. is Executive Director of The International Coffee Organization ( ICO - https://icocoffee.org/ ), an organization focused on strengthening the global coffee sector and promoting it’s sustainable expansion in a market-based environment for the benefit of all actors in the Global Coffee Value Chain.Dr. Nogueira comes from a family of coffee producers, and started her career at PwC Consulting, where she was a partner and worked for 15 years. She started working directly with coffee in 2002, always focusing on niche markets. Dr. Nogueira served as executive director at the Brazilian Specialty Coffee Association (BSCA) from 2007 through April 2022 and took over as Executive Director at the International Coffee Organization in May 2022. Dr. Nogueira holds a Ph.D. in Administration/Marketing from Rosario National University in Argentina, a BS in Systems Engineering and Administration from Pontifical Catholic University of Rio de Janeiro (PUC-RJ) and MBAs and post-MBA focusing on Management, Marketing and Advanced Project Management from Fundação Getulio Vargas-Rio de Janeiro (FGV-RJ).The ICO was established in 1963 under the aegis of the United Nations and following the approval of the first International Coffee Agreement in 1962. And is the only intergovernmental organization for coffee, bringing together exporting and importing Governments. It currently represents 93% of world coffee production and 63% of world consumption.Important Link - The Center for Circular Economy in Coffee - https://www.circulareconomyincoffee.org/ #Coffee #InternationalCoffeeOrganization #CircularEconomy #ICO #Macroeconomics #CoffeeValueChain #VanusiaNogueira #MinasGerais #Brazil #Sustainability #Producers #Growers #UnitedNations #SpecialtyCoffee #Beverages #Tea #Cocoa #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. Oren Milstein, Ph.D. is CEO and Board Member of StemRad ( https://stemrad.com/ ), a world leader in the provision of personal radiation protection solutions and is the first company to offer life-saving protection from penetrating ionizing radiation and is making the lives of first responders, military personnel, utility personnel, medical teams, and astronauts safer without compromising mission objectives. Comprised of radiation biology experts, nuclear physicists, designers, and engineers and backed by dozens of prominent doctors and scientists including three Nobel Laureates, StemRad provides cutting-edge technology to protect these heroes on Earth and beyond.Dr. Milstein co-founded StemRad in 2011, shortly after the Fukushima Daiichi nuclear disaster in Japan. He has been leading R&D efforts ever since and was appointed CEO in February of 2016. Dr. Milstein has more than 12 years of Life Sciences research experience; formerly, Dr. Milstein was an European Molecular Biology Organization (EMBO) fellow at NYU’s Skirball Institute of Biomolecular Medicine, where his research provided basic insights into the mechanism of T cell activation. Later in his career, as an NIH fellow at the Scripps Research Institute, he discovered a novel mechanism for iron deficiency anemia. Subsequently, Dr. Milstein focused his research on radiation-induced autoimmune hemolytic anemia. Dr. Milstein received his Ph.D. degree from The Weizmann Institute of Science in 2008, where he developed novel strategies for successful bone marrow transplantation into irradiated subjects. He received his B.Sc., Magna Cum Laude, from The Hebrew University in Jerusalem. His research has resulted in several peer-reviewed publications and patents.#OrenMilstein #StemRad #PersonalRadiationProtection #GammaRadiation #Fukushima #Chernobyl #Israel #Nagasaki #Hiroshima #NuclearAccidents #USANCA #CBRN #WMD #DTRA #BoneMarrow #NuclearWar #Putin #Iran #KimJungUn #NASA #LockheedMartin #NationalGuardSupport the show

Send us a textDr. Jeffrey DellaVolpe, MD is Medical Director of the Adult Extracorporeal Membrane Oxygenation (ECMO) Program at Methodist Hospital, San Antonio, Texas. He is also the Medical Director of the Cardiovascular Intensive Care Unit at Methodist Healthcare System and the Texas IPS Critical Care Service Line ( https://texasips.com/jeffrey-dellavolpe-md/ ). He also serves as chair of the Joint Society of Critical Care Medicine/Extracorporeal Life Support Organization Task Force and has created a platform for ECMO training and ECMO transport ( https://ecmotransports.com/about/ ).ECMO is a form of extracorporeal life support, providing prolonged cardiac and respiratory support to persons whose heart and lungs are unable to provide an adequate amount of oxygen, gas exchange or blood supply (perfusion) to sustain life.Dr. DellaVolpe served as a Flight Surgeon with the 27th Special Operations Wing where he deployed twice in support of Operation Enduring Freedom – Trans Sahara. After completing his fellowship, he was assigned to the San Antonio Military Medical Center where he served as a critical care physician and a member of the 59th Medical Wing Critical Care Air Transport Team and Acute Lung Rescue Team.Dr. DellaVolpe is originally from Newport, RI. After receiving his bachelor’s degree at Dartmouth College, he went on to attend medical school at Tulane University School of Medicine. He then completed his residency in Internal Medicine at Tulane Medical Center and his fellowship in Critical Care Medicine at the University of Pittsburgh Medical Center.Dr. DellaVolpe wrote The ECMO Book, published Elsevier Health Sciences, in 2023 ( https://www.us.elsevierhealth.com/the-ecmo-book-9780443111983.html ).#JeffreyDellaVolpe #MedicalDirector #ExtracorporealMembraneOxygenation #ECMO #MethodistHospital #SanAntonio #Texas #Cardiovascular #IntensiveCare #CriticalCare #LifeSupport #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast  #STEM #Innovation #Technology #Science #ResearchSupport the show

Send us a textDr. William Padula, PhD, MS, MSc, is Assistant Professor, Pharmaceutical & Health Economics and Fellow, Schaeffer Center for Health Policy & Economics, at the Alfred E. Mann School of Pharmacy & Pharmaceutical Sciences, University of Southern California ( https://healthpolicy.usc.edu/author/william-padula-phd/ ). His research explores the theoretical foundations of medical cost-effectiveness analysis, especially pertaining to issues around the value of vaccines, healthcare delivery and patient safety in hospitals for acquired conditions such as pressure injuries. He has received grant funding in the form of a Career Development Award from the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, and the PhRMA Foundation Frontier Award. He has authored 100+ scientific papers, letters and book chapters that have been published in leading medical, economic, and health policy journals. Dr. Padula is also Co-Founder & Principal of Stage Analytics ( https://stageanalytics.com/william-v-padula-phd/ ), a consulting firm that is committed to providing the highest quality of scientific solutions to advance health care. Dr. Padula is an Associate Editor of Value in Health, and serves on the editorial boards of Applied Health Economics and Health Policy and Journal of Clinical Nursing. His work has been featured in the New York Times, The Atlantic, The Hill, Forbes and other media. He is a past recipient of the Award for Excellence in Health Economics and Outcomes Research from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR); the Academy Health Outstanding Dissertation Award; and the Society for Advancement in Wound Care (SAWC) Young Investigator Award. He served as President for the U.S. National Pressure Injury Advisory Panel (NPIAP) from 2021-2022. He was also Commissioner for the American Nurses Credentialing Center (ANCC) Magnet® Recognition Program from 2016-2019. Dr. Padula has previously held appointments as an Assistant Professor at the Johns Hopkins Bloomberg School of Public Health in Baltimore, USA, and as a postdoctoral fellow at The University of Chicago. He was a visiting scholar at the University of York Centre for Health Economics in York, UK, the Oxford Institute for Nursing, Midwifery and Allied Health in Oxford, UK, and the University of Technology Sydney in Sydney, Australia. He received his B.S. in Chemical Engineering from Northwestern University, M.S. in Evaluative Clinical Science from Dartmouth College, M.S. in Data Analytics from University of Chicago, and Ph.D. in Pharmaceutical Economics from University of Colorado. #HealthEconomics #USC #WoundCare #Pharmacy #PressureSores #Pharmaceuticals #WilliamPadula #HealthcareValue #Outcomes #WastefulSpending #Medicare #Medicaid #progresspotentialandpossibilities #IraPastor #podcast #podcaster #viralpodcast #STEM #Innovation #Technology #Science #Research Support the show

Send us a textDr. Raj Yavatkar, Ph.D. is Chief Technology Officer at Juniper Networks ( https://www.juniper.net/us/en/the-feed/topics/raj-yavatkar.html ), where he has responsibility for charting the company’s technology strategy, leading and executing the company’s critical innovations and products for intelligent self-driving networks, security, Mobile Edge Cloud, network virtualization, packet-optical integration, and hybrid cloud. A technology and products pioneer throughout his career, Dr. Yavatkar has envisioned how emerging technologies can be applied to creatively solve enterprise and business problems ahead of competitors to help establish new product lines. Before joining Juniper, Dr. Yavatkar was at Google (GCP), where he led a large team of engineers to deliver cloud networking infrastructure and products for Google Cloud customers. Prior to that at VMware, he ideated a new product concept to address the private/hybrid cloud markets by defining VMware Cloud Foundation—an easy way to deploy and manage virtual clouds—leading a large product team to successfully deliver product to market. He started his career at Intel, rising to the position of Intel Fellow, a position he held for 10 years. During his various leadership roles there, Dr. Yavatkar was responsible for driving new product and R&D initiatives in many areas of software. He brings a wealth of experience in emerging technologies. He has been awarded more than 45 patents, published over 60 research papers, authored 5 Internet standards, and co-authored a book on internet quality of service. He is an IEEE Fellow and holds a PhD in Computer Science from Purdue University. Support the show

Send us a textDr. Jasneet Bhullar, MD, MS, is a colorectal surgeon and member of the general surgery team, Ascension Providence Hospital, Michigan State University College of Human Medicine ( https://healthcare.ascension.org/find-care/provider/1316177876/jasneet-bhullar ), where he provides both surgical and non-surgical treatments for a range of conditions including pelvic floor disorders, fecal incontinence, colon and rectal cancer, hemorrhoids, and other complex issues of the colon and rectal system.Dr. Bhullar is also a practitioner with the Cornerstone Medical Group ( https://www.cornerstonemedgroup.com/physicians-staff/jasneet-bhullar-md/ ), a multi-specialty group consisting of primary care and specialty physicians in the metro Detroit area, where he was responsible for earning recognition as an Medtronic InterStim™ Center of Excellence for his work with their MRI-compatible implantable neuromodulation technology for Fecal incontinence (FI).Dr. Bhullar earned his medical degree at Guru Gobind Singh Medical College in India and completed residencies in general surgery through Government Medical College, India and Providence Hospital and Medical Centers — Michigan State University, and did a fellowship in colon and rectal surgery at the University of Minnesota.  He is board-certified by the American Board of Surgery (ABS) and the American Board of Colon and Rectal Surgery (ABCRS).Support the show

Send us a textCary Claiborne is CEO of Adial Pharmaceuticals ( https://www.adial.com/ ), a clinical-stage biopharma company focused on developing therapies for the treatment of addiction and related diseases, specifically Alcohol Use Disorder (AUD). In the U.S. alone, an estimated 35 million people suffer from AUD, resulting in significant health, social and financial costs. Current treatment options present significant barriers to patient adoption, including abstinence and side effects, which can lead to social stigmatization.Mr. Claiborne has over three decades of experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies. Most recently, Mr. Claiborne served as Chief Financial Officer and director of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses. He led Indivior’s spin-off from its then parent company, Reckitt Benckiser, to become an independent, publicly traded company. Prior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt. Before joining Sucampo, Mr. Claiborne served as CFO and Corporate Secretary of Osiris Therapeutics, Inc. during the company’s initial public offering.Mr. Claiborne currently sits on the boards of NeuroSense Therapeutics, a clinical-stage drug development company that is advancing a treatment for people living with amyotrophic lateral sclerosis, and CytRx Corporation, a biopharmaceutical company focused on discovering and developing new cancer therapeutics. Mr. Claiborne graduated from Rutgers University with a B.A. in Business Administration and earned his M.B.A from Villanova University and was a National Association of Corporate Directors (NACD) Governance Fellow.Support the show

Send us a textDr. Valerie Sarisky-Reed, Ph.D. ( https://www.energy.gov/eere/person/valerie-sarisky-reed ) is the Director of the Bioenergy Technologies Office (BETO), in the Office of Energy Efficiency and Renewable Energy (EERE), at the U.S. Department of Energy's (DOE). In this role, she manages efforts to improve performance, lower costs, and accelerate market entry of bioenergy technologies. She assists in overseeing strategic planning to meet aggressive goals covered by the BETO research and development budget of approximately $250M annually, working with the U.S. Department of Energy's (DOE) national laboratories, academia, and industry. The Bioenergy Technologies Office current focus areas include scaling up renewable hydrocarbon fuel technologies with an emphasis on sustainable aviation fuels as well as on the recycle and upcycle of plastics through DOE’s Plastics Innovation Challenge which aims to reduce ocean-bound plastic waste.Dr. Sarisky-Reed has more than 30 years of experience in addressing energy and environmental issues faced by the United States and globally. In addition to her programmatic activities, she is a founding member of the Metabolic Engineering Working Group, chartered by the Biotechnology Research Subcommittee, an inter-agency coordinating committee under the Office of Science and Technology Policy.Dr. Sarisky-Reed also spent two years serving the chief scientist at the U.S. Department of Agriculture, helping to build bridges between DOE and the U.S. Department of Agriculture in support of the bioeconomy.  She also served as acting director for EERE's Wind Energy Technologies Office where she enabled the development of the most recent Multi-Year Program Plan with a heavy focus on bringing offshore wind to the United States.Dr. Sarisky-Reed holds a Ph.D. in biochemistry from Georgetown University, and is a graduate of the U.S. Department of Commerce’s Senior Executive Service Career Development Program.Important Link - Bioenergy Technologies Office 2023 Multi-Year Program Plan - https://www.energy.gov/sites/default/files/2023-03/beto-mypp-fy23.pdfSupport the show

Send us a textProf. Noga Kronfeld-Schor, Ph.D. is Principal Investigator and Chair, Department of Zoology at Tel Aviv University ( https://en-lifesci.tau.ac.il/profile/nogaks ) where her research centers on environmental physiology with a focus on biological rhythms of diverse vertebrate species.  Her research asks questions regarding the consequences and adaptive significance of these rhythms, as well as the interaction between physiological and endocronological processes and the evolutionary ecology of organisms and communities.  She also is involved in studying the impact of events like global warming and light pollution on biodiversity, as well as on human and environmental health. Prof. Kronfeld-Schor also serves as Chief Scientist of the Israeli Ministry of Environmental Protection ( https://www.gov.il/en/departments/units/chief_scientist_office ), where she provides strategic, scientific, and technological consultations that are aimed at promoting the environmental field in Israel in accordance with advancements being made in leading developed countries and OECD member countries. Prof. Kronfeld-Schor has a BSc in Biology, an MSc in Zoology, magna cum laude and Ph.D. in Zoology, all from Tel Aviv University, and was a post-doctoral fellow at Boston University, in Zoology & Neuroendocrinology.In addition to the roles mentioned above, Prof. Kronfeld-Schor has also served as a member of the board of directors of the Society for the Protection of Nature, was a member of the plenum and was head of the Scientific and Professional Committee of the Nature and Parks Authority, and has managed numerous national and international projects, and advised various government bodies and international organizations.Support the show

Send us a textDr. David Boucher, Ph.D. is Director, Infectious Disease Preparedness and Response, Administration for Strategic Preparedness and Response, U.S. Department of Health and Human Services ( https://aspr.hhs.gov/Pages/Home.aspx ).The HHS Administration for Strategic Preparedness and Response (ASPR) leads the nation's medical and public health preparedness for, response to, and recovery from disasters and other public health emergencies.ASPR collaborates with hospitals, healthcare coalitions, biotech firms, community members, state, local, tribal, and territorial governments, and other partners across the country to improve readiness and response capabilities.Dr. Boucher previously held several other critical roles in the organization, including as Chief of the Antivirals & Antitoxins branch at BARDA’s Anthrax, Botulinum, Ebola and Smallpox therapeutics program office, Acting Director for the Administration for Strategic Preparedness and Response's Office of Industrial Base Management and Supply Chain (IBM/SC) and serving as HHS’s lead negotiator for product development/procurement agreements for COVID-19 medical countermeasures.Dr. Boucher has a Bachelor of Science (B.S.), Genetics, and a Doctor of Philosophy (PhD), Biochemistry and Molecular Biology from University of California, Davis.Support the show